Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects
Authors:
- G Justus HofmeyrGHG Justus Hofmeyr
- A Metin GülmezogluAGA Metin Gülmezoglu
- Natalia NovikovaNNNatalia Novikova
- Verena LinderVLVerena Linder
- 1 September 2009
- journal article
- review article
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 87 (9) , 666-667
Abstract
To review maternal deaths and the dose-related effects of misoprostol on blood loss and pyrexia in randomized trials of misoprostol use for the prevention or treatment of postpartum haemorrhage. We searched the Cochrane Controlled Trials Register and Pubmed, without language restrictions, for “(misoprostol AND postpartum) OR (misoprostol AND haemorrhage) OR (misoprostol AND hemorrhage)”, and we evaluated reports identified through the Cochrane Pregnancy and Childbirth Group search strategy. Randomized trials comparing misoprostol with either placebo or another uterotonic to prevent or treat postpartum haemorrhage were checked for eligibility. Data were extracted, tabulated and analysed with Reviewer Manager (RevMan) 4.3 software. We included 46 trials with more than 40 000 participants in the final analysis. Of 11 deaths reported in 5 trials, 8 occurred in women receiving ≥ 600 µg of misoprostol (Peto odds ratio, OR: 2.49; 95% confidence interval, CI: 0.76–8.13). Severe morbidity, defined as the need for major surgery, admission to intensive care, organ failure or body temperature ≥ 40 °C, was relatively infrequent. In prevention trials, severe morbidity was experienced by 16 of 10 281 women on misoprostol and by 16 of 10 292 women on conventional uterotonics; in treatment trials, it was experienced by 1 of 32 women on misoprostol and by 1 of 32 women on conventional uterotonics. Misoprostol recipients experienced more adverse events than placebo recipients: 8 of 2070 versus 5 of 2032, respectively, in prevention trials, and 5 of 196 versus 2 of 202, respectively, in treatment trials. Meta-analysis of direct and adjusted indirect comparisons of the results of randomized trials showed no evidence that 600 µg are more effective than 400 µg for preventing blood loss ≥ 1000 ml (relative risk, RR: 1.02; 95% CI: 0.71–1.48). Pyrexia was more than twice as common among women who received ≥□600 µg rather than 400 µg of misoprostol (RR: 2.53; 95% CI: 1.78–3.60). Further research is needed to more accurately assess the potential beneficial and harmful effects of misoprostol and to determine the smallest dose that is effective and safe. In this review, 400 µg of misoprostol were found to be safer than ≥ 600 µg and just as effective.Keywords
This publication has 59 references indexed in Scilit:
- Misoprostol versus oxytocin for the reduction of postpartum blood lossInternational Journal of Gynecology & Obstetrics, 2007
- Evidence-based interventions to prevent postpartum hemorrhage: Translating research into practiceInternational Journal of Gynecology & Obstetrics, 2006
- A Double-Blind Randomized Controlled Trial of Oral Misoprostol and Intramuscular Syntometrine in the Management of the Third Stage of LaborGynecologic and Obstetric Investigation, 2006
- Rectal misoprostol vs. 15‐methyl prostaglandin F2α for the prevention of postpartum hemorrhageInternational Journal of Gynecology & Obstetrics, 2006
- Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean sectionInternational Journal of Gynecology & Obstetrics, 2005
- Oral misoprostol in the third stage of laborInternational Journal of Gynecology & Obstetrics, 2005
- Placebo‐controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhageJournal of Obstetrics and Gynaecology Research, 2005
- Buccal misoprostol to prevent hemorrhage at cesarean delivery: A randomized studyAmerican Journal of Obstetrics and Gynecology, 2005
- Misoprostol to treat postpartum haemorrhage: a systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- A pilot‐randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of laborActa Obstetricia et Gynecologica Scandinavica, 2004